SCHEMBL14596184

SCHEMBL14596184

CC(C)NC(=O)N(C)Cc1nc(NCCCN(C)C)c2ccccc2n1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.54
MAPK1 P28482 1/20 0.54
FLT3 P36888 9/20 0.51
RAD52 P43351 4/20 0.51
POLB P06746 3/20 0.50
TOP2A P11388 2/20 0.50
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
SLC2A1 P11166 1/20 0.49
APOBEC3A P31941 1/20 0.49
RAB9A P51151 1/20 0.49
APOBEC3G Q9HC16 1/20 0.49
RXFP1 Q9HBX9 1/20 0.48
ACHE P22303 2/20 0.47
BCHE P06276 1/20 0.47
ACP1 P24666 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14596194 0.91 FLT3 (0.51) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596193 0.91 FLT3 (0.51) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596399 0.91 FLT3 (0.51) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596225 0.90 ALDH1A1 (0.54) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596187 0.88 ALDH1A1 (0.54) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596186 0.87 ALDH1A1 (0.53) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596185 0.86 ALDH1A1 (0.52) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596059 0.86 ALDH1A1 (0.52) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596196 0.86 ACHE (0.53) ALDH1A1MAPK1FLT3RAD52POLB
SCHEMBL14596191 0.85 ALDH1A1 (0.49) ALDH1A1MAPK1FLT3RAD52POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015774-A1 Quinazoline derivatives useful in cancer treatment TP53, TP53BP1, ACIN1 ALDH1A1 1994/4885MAPK1 2089/4885FLT3 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.